查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
间质性膀胱炎的全球市场 - 产业趋势与预测(～2029年)
市场调查报告书
商品编码
1145414

间质性膀胱炎的全球市场 - 产业趋势与预测(～2029年)

Global Interstitial Cystitis Market - Industry Trends and Forecast to 2029
出版日期: | 出版商: Data Bridge Market Research | 英文 444 Pages | 商品交期: 请询问到货日

价格

全球间质性膀胱炎的市场规模，预计在2022年～2029年的预测期间中记录10.5％相当的年复合成长率。

推动间质性膀胱炎的全球市场成长的主要原因，是间质性膀胱炎的盛行率的上升，和老年人口增加。

本报告提供全球间质性膀胱炎市场调查，市场促进因素和阻碍因素，机会和课题，各市场区隔、地区的市场明细，竞争情形，主要企业简介等彙整资讯。

目录

第1章 简介

第2章 市场区隔

第3章 摘要整理

第4章 重要考察

  • PESTEL分析
  • 波特的五力分析
  • 间质性膀胱炎治疗市场开发平台分析
  • 流行病学

第5章 全球间质性膀胱炎市场:法规

  • 食品药物管理局(FDA)指南
  • 欧洲药品管理局(EMA)指南
  • 日本法规指导

第6章 市场概要

  • 促进因素
  • 阻碍因素
  • 机会
  • 课题

第7章 全球间质性膀胱炎市场:各重症度

  • 概要
  • 轻度～中等度
  • 中间度～重度

第8章 全球间质性膀胱炎市场:各治疗类型

  • 概要
  • 药物
    • 止痛药
    • 抗组织胺药物
    • 三环抗忧郁药物
    • 免疫抑制剂
    • 聚戊醣多硫化钠
    • 其他
  • 膀胱内注射
    • 二甲基亚砜
    • 肝素
    • 其他
  • 肉毒桿菌A
  • 手术
    • 高频治疗
    • 切除
    • 膀胱扩大术
  • 神经刺激

第9章 全球间质性膀胱炎市场:各给药途径

  • 概要
  • 口服
    • 锭剂
    • 胶囊
    • 其他
  • 非口服
  • 膀胱内
  • 局部
  • 其他

第10章 全球间质性膀胱炎市场:各购买方法

  • 概要
  • 商店
  • 处方

第11章 全球间质性膀胱炎市场:各患者类型

  • 概要
  • 大人
  • 儿童

第12章 全球间质性膀胱炎市场:各终端用户

  • 概要
  • 医院
  • 诊所
  • 居家医疗
  • 其他

第13章 全球间质性膀胱炎市场:各流通管道

  • 概要
  • 直接竞标
  • 零售
    • 药局
    • 网路零售流通管道
    • 其他
  • 其他

第14章 全球间质性膀胱炎市场:各地区

  • 概要
  • 北美
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 义大利
    • 西班牙
    • 土耳其
    • 俄罗斯
    • 荷兰
    • 瑞士
    • 比利时
    • 其他欧洲
  • 亚太地区
    • 中国
    • 日本
    • 印度
    • 澳洲
    • 韩国
    • 泰国
    • 新加坡
    • 印尼
    • 马来西亚
    • 越南
    • 菲律宾
    • 其他亚太地区
  • 南美
    • 巴西
    • 阿根廷
    • 其他南美
  • 中东、非洲
    • 沙乌地阿拉伯
    • 南非
    • 阿拉伯联合大公国
    • 埃及
    • 以色列
    • 其他中东、非洲

第15章 全球间质性膀胱炎市场:企业形势

  • 企业占有率分析:世界
  • 企业占有率分析:北美
  • 企业占有率分析:欧洲
  • 企业占有率分析:亚太地区

第16章 SWOT分析

第17章 企业简介

  • TEVA PHARMACEUTICALS INDUSTRIES LTD.
  • SANDOZ AG(NOVARTIS AG的子公司)
  • HIKMA PHARMACEUTICALS PLC
  • DR. REDDY'S LABORATORIES LTD
  • BAYER AG
  • AMNEAL PHARMACEUTICAL LLC.
  • APOTEX
  • AUROBINDO PHARMA USA
  • AVET PHARMACEUTICALS INC.
  • ALVOGEN
  • ACCORD-UK LTD
  • GLAXOSMITHKLINE PLC
  • JOHNSON & JOHNSON SERVICES, INC.
  • LANNETT
  • PRESTIGE CONSUMER HEALTHCARE
  • PFIZER INC.
  • RECKITT BENCKISER GROUP PLC.
  • SUN PHARMACEUTICAL INDUSTRIES LTD.
  • STRIDES PHARMA SCIENCE LIMITED.
  • VIATRIS INC.
  • VISTA PHARM INC.
  • ZYDUS PHARMACEUTICALS INC.,

第18章 问卷调查

第19章 相关报告

The global interstitial cystitis market is projected to register a substantial CAGR of 10.5% in the forecast period of 2022 to 2029. The new market report contains data for the historic year 2020, the base year of calculation is 2021, and the forecast period is 2022 to 2029.

Market Segmentation:

By Severity (Mild to Moderate and Moderate to Severe), Treatment Type (Medications, Bladder Instillations, Botulinum Toxin A, Nerve Stimulation and Surgery), Route of Administration (Oral, Parenteral, Intravesical, Topical, and Others), Mode of Purchase (Over The Counter and Prescription), Patient Type (Pediatric and Adults), End User (Hospitals, Clinics, Home Healthcare, and Others), Distribution Channel (Direct Tender, Retail Sales, and Others), Country (U.S., Canada, Mexico, Germany, Italy, U.K., France, Spain, Netherland, Belgium, Switzerland, Turkey, Russia, Rest of Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific, Brazil, Argentina, Rest of South America, South Africa, Saudi Arabia, UAE, Egypt, Israel, Rest of the Middle East and Africa), Industry Trends and Forecast to 2029.

Some of the major factors contributing to the growth of the global interstitial cystitis market are:

  • Rise in prevalence of interstitial cystitis
  • Increase in the geriatric population

Market Players:

Some of the major players operating in the global interstitial cystitis market are:

  • Alvogen
  • Hikma Pharmaceuticals
  • Sandoz AG
  • Sun Pharmaceutical Industries Ltd.
  • Accord-UK Ltd
  • Avet Pharmaceuticals Inc.
  • Lannett
  • Viatris Inc.
  • Pfizer, Inc.
  • Strides Pharma Science Limited
  • GlaxoSmithKline plc.
  • Prestige Consumer Healthcare Inc
  • Amneal Pharmaceuticals LLC
  • Zydus Pharmaceuticals, Inc.
  • Apotex Inc.
  • Aurobindo Pharma USA
  • VistaPharm, Inc.
  • Dr. Reddy's Laboratories, Inc.
  • Teva Pharmaceuticals, Inc.
  • Bayer AG
  • Reckitt Benckiser Group PLC
  • Janssen Pharmaceuticals, Inc.

TABLE OF CONTENTS

1 INTRODUCTION 57

  • 1.1 OBJECTIVES OF THE STUDY 57
  • 1.2 MARKET DEFINITION 57
  • 1.3 OVERVIEW OF GLOBAL INTERSTITIAL CYSTITIS MARKET 57
  • 1.4 LIMITATIONS 58
  • 1.5 MARKETS COVERED 59

2 MARKET SEGMENTATION 61

  • 2.1 MARKETS COVERED 61
  • 2.2 GEOGRAPHICAL SCOPE 62
  • 2.3 YEARS CONSIDERED FOR THE STUDY 63
  • 2.4 CURRENCY AND PRICING 63
  • 2.5 DBMR TRIPOD DATA VALIDATION MODEL 64
  • 2.6 MULTIVARIATE MODELLING 67
  • 2.7 TYPE LIFELINE CURVE 67
  • 2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 68
  • 2.9 DBMR MARKET POSITION GRID 69
  • 2.10 MARKET APPLICATION COVERAGE GRID 70
  • 2.11 VENDOR SHARE ANALYSIS 71
  • 2.12 SECONDARY SOURCES 72
  • 2.13 ASSUMPTIONS 72

3 EXECUTIVE SUMMARY 73

4 PREMIUM INSIGHTS 75

  • 4.1 PESTEL ANALYSIS 77
  • 4.2 PORTER'S FIVE FORCES 78
  • 4.3 PIPELINE ANALYSIS FOR INTERSTITIAL CYSTITIS TREATMENT MARKET 79
  • 4.4 EPIDEMIOLOGY 80

5 GLOBAL INTERSTITIAL CYSTITIS MARKET: REGULATIONS 81

  • 5.1 FOOD AND DRUG ADMINISTRATION (FDA) GUIDELINES 81
  • 5.2 EUROPEAN MEDICINES AGENCY (EMA) GUIDELINES 82
  • 5.3 JAPAN REGULATORY GUIDANCE 83

6 MARKET OVERVIEW 84

  • 6.1 DRIVERS 86
    • 6.1.1 INCREASED PREVALENCE OF INTERSTITIAL CYSTITIS (IC) 86
    • 6.1.2 RISE IN HEALTHCARE EXPENDITURE 86
    • 6.1.3 STRATEGIC INITIATIVES OF KEY PLAYERS 87
    • 6.1.4 INCREASE IN R&D EFFORTS IN THE HEALTHCARE INDUSTRY 87
    • 6.1.5 RISING DISEASE MANAGEMENT PROGRAMS 87
  • 6.2 RESTRAINTS 88
    • 6.2.1 HIGH COST OF TREATMENT OF INTERSTITIAL CYSTITIS 88
    • 6.2.2 LACK OF AWARENESS ABOUT BLADDER DISORDERS-RELATED PROBLEMS 88
    • 6.2.3 DEARTH OF SKILLED PROFESSIONALS 89
  • 6.3 OPPORTUNITIES 89
    • 6.3.1 FAVORABLE REIMBURSEMENT SCENARIO 89
    • 6.3.2 INCREASE IN DRUG APPROVALS AND LAUNCHES 90
    • 6.3.3 IMPROVING HEALTHCARE SYSTEM 90
    • 6.3.4 COMBINATION OF DIFFERENT TARGET THERAPIES 90
  • 6.4 CHALLENGES 91
    • 6.4.1 STRINGENT GOVERNMENT REGULATIONS ON NEW PRODUCTS APPROVAL 91
    • 6.4.2 PATENT EXPIRY OF DRUGS 92

7 GLOBAL INTERSTITIAL CYSTITIS MARKET, BY SEVERITY 93

  • 7.1 OVERVIEW 94
  • 7.2 MILD TO MODERATE 97
  • 7.3 MODERATE TO SEVERE 97

8 GLOBAL INTERSTITIAL CYSTITIS MARKET, BY TREATMENT TYPE 98

  • 8.1 OVERVIEW 99
  • 8.2 MEDICATIONS 102
    • 8.2.1 ANALGESICS 102
      • 8.2.1.1 NONSTEROIDAL ANTI-INFLAMMATORY DRUGS 103
        • 8.2.1.1.1 IBUPROFEN 103
        • 8.2.1.1.2 NAPROXEN 103
        • 8.2.1.1.3 OTHERS 103
      • 8.2.1.2 ACETAMINOPHEN 103
      • 8.2.1.3 NON-NARCOTIC PAIN MEDICATION 103
        • 8.2.1.3.1 METHENAMINE 104
        • 8.2.1.3.2 PHENAZOPYRIDINE 104
        • 8.2.1.3.3 OTHERS 104
      • 8.2.1.4 NARCOTIC PAIN MEDICATION 104
        • 8.2.1.4.1 CODEINE 105
        • 8.2.1.4.2 HYDROCODONE 105
        • 8.2.1.4.3 OXYCODONE 105
        • 8.2.1.4.4 OXYMORPHONE 105
        • 8.2.1.4.5 MORPHINE 105
        • 8.2.1.4.6 HYDROMORPHONE 105
        • 8.2.1.4.7 METHADONE 106
        • 8.2.1.4.8 OTHERS 106
    • 8.2.2 ANTIHISTAMINES 106
      • 8.2.2.1 LORATADINE 106
      • 8.2.2.2 HYDROXYZINE 106
      • 8.2.2.3 OTHERS 106
    • 8.2.3 TRICYCLIC ANTIDEPRESSANTS 106
      • 8.2.3.1 AMITRIPTYLINE 107
      • 8.2.3.2 IMIPRAMINE 107
      • 8.2.3.3 OTHERS 107
    • 8.2.4 IMMUNOSUPPRESSANTS 107
      • 8.2.4.1 CYCLOSPORINE 107
      • 8.2.4.2 MYCOPHENOLATE 107
      • 8.2.4.3 OTHERS 108
    • 8.2.5 PENTOSAN POLYSULFATE SODIUM 108
    • 8.2.6 OTHERS 108
      • 8.2.6.1 ALPHA BLOCKERS 108
        • 8.2.6.1.1 DOXAZOSIN 109
        • 8.2.6.1.2 TERAZOSIN 109
        • 8.2.6.1.3 TAMSULOSIN 109
        • 8.2.6.1.4 OTHERS 109
      • 8.2.6.2 AMPHETAMINES 109
      • 8.2.6.3 LEUKOTRIENE INHIBITORS 109
        • 8.2.6.3.1 MONTELUKAST 110
        • 8.2.6.3.2 ZAFIRLUKAST 110
        • 8.2.6.3.3 OTHERS 110
      • 8.2.6.4 OTHERS 110
  • 8.3 BLADDER INSTILLATIONS 110
    • 8.3.1 DIMETHYL SULFOXIDE 111
    • 8.3.2 HEPARIN 111
    • 8.3.3 OTHERS 111
  • 8.4 BOTULINUM TOXIN A 111
  • 8.5 SURGERY 112
    • 8.5.1 FULGURATION 112
    • 8.5.2 RESECTION 112
    • 8.5.3 BLADDER AUGMENTATION 112
  • 8.6 NERVE STIMULATIONS 112

9 GLOBAL INTERSTITIAL CYSTITIS MARKET, BY ROUTE OF ADMINISTRATION 114

  • 9.1 OVERVIEW 115
  • 9.2 ORAL 118
    • 9.2.1 TABLETS 118
      • 9.2.1.1 EXTENDED RELEASE 119
      • 9.2.1.2 IMMEDIATE RELEASE 119
    • 9.2.2 CAPSULES 119
    • 9.2.3 OTHERS 119
  • 9.3 PARENTERAL 119
  • 9.4 INTRAVESICAL 120
  • 9.5 TOPICAL 120
  • 9.6 OTHERS 121

10 GLOBAL INTERSTITIAL CYSTITIS MARKET, BY MODE OF PURCHASE 122

  • 10.1 OVERVIEW 123
  • 10.2 OVER THE COUNTER 126
  • 10.3 PRESCRIPTION 126

11 GLOBAL INTERSTITIAL CYSTITIS MARKET, BY PATIENT TYPE 127

  • 11.1 OVERVIEW 128
  • 11.2 ADULTS 131
  • 11.3 PEDIATRIC 131

12 GLOBAL INTERSTITIAL CYSTITIS MARKET, BY END USER 132

  • 12.1 OVERVIEW 133
  • 12.2 HOSPITALS 136
  • 12.3 CLINICS 136
  • 12.4 HOME HEALTHCARE 137
  • 12.5 OTHERS 137

13 GLOBAL INTERSTITIAL CYSTITIS MARKET, BY DISTRIBUTION CHANNEL 138

  • 13.1 OVERVIEW 139
  • 13.2 DIRECT TENDER 142
  • 13.3 RETAIL SALES 142
    • 13.3.1 PHARMACY STORES 143
    • 13.3.2 ONLINE RETAIL CHANNEL 143
    • 13.3.3 OTHERS 143
  • 13.4 OTHERS 143

14 GLOBAL INTERSTITIAL CYSTITIS MARKET, BY GEOGRAPHY 144

  • 14.1 OVERVIEW 145
  • 14.2 NORTH AMERICA 151
    • 14.2.1 U.S. 162
    • 14.2.2 CANADA 168
    • 14.2.3 MEXICO 174
  • 14.3 EUROPE 180
    • 14.3.1 GERMANY 191
    • 14.3.2 U.K. 197
    • 14.3.3 FRANCE 203
    • 14.3.4 ITALY 209
    • 14.3.5 SPAIN 215
    • 14.3.6 TURKEY 221
    • 14.3.7 RUSSIA 227
    • 14.3.8 NETHERLANDS 233
    • 14.3.9 SWITZERLAND 239
    • 14.3.10 BELGIUM 245
    • 14.3.11 REST OF EUROPE 251
  • 14.4 ASIA-PACIFIC 252
    • 14.4.1 CHINA 263
    • 14.4.2 JAPAN 269
    • 14.4.3 INDIA 275
    • 14.4.4 AUSTRALIA 281
    • 14.4.5 SOUTH KOREA 287
    • 14.4.6 THAILAND 293
    • 14.4.7 SINGAPORE 299
    • 14.4.8 INDONESIA 305
    • 14.4.9 MALAYSIA 311
    • 14.4.10 VIETNAM 317
    • 14.4.11 PHILIPPINES 323
    • 14.4.12 REST OF ASIA-PACIFIC 329
  • 14.5 SOUTH AMERICA 330
    • 14.5.1 BRAZIL 341
    • 14.5.2 ARGENTINA 347
    • 14.5.3 REST OF SOUTH AMERICA 353
  • 14.6 MIDDLE EAST AND AFRICA 354
    • 14.6.1 SAUDI ARABIA 365
    • 14.6.2 SOUTH AFRICA 371
    • 14.6.3 UAE 377
    • 14.6.4 EGYPT 383
    • 14.6.5 ISRAEL 389
    • 14.6.6 REST OF MIDDLE EAST AND AFRICA 395

15 GLOBAL INTERSTITIAL CYSTITIS MARKET: COMPANY LANDSCAPE 396

  • 15.1 COMPANY SHARE ANALYSIS: GLOBAL 396
  • 15.2 COMPANY SHARE ANALYSIS: NORTH AMERICA 397
  • 15.3 COMPANY SHARE ANALYSIS: EUROPE 398
  • 15.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC 399

16 SWOT ANALYSIS 400

17 COMPANY PROFILE 401

  • 17.1 TEVA PHARMACEUTICALS INDUSTRIES LTD. 401
    • 17.1.1 COMPANY SNAPSHOT 401
    • 17.1.2 REVENUE ANALYSIS 401
    • 17.1.3 PRODUCT PORTFOLIO 402
    • 17.1.4 RECENT DEVELOPMENTS 402
  • 17.2 SANDOZ AG (A SUBSIDIARY OF NOVARTIS AG) 403
    • 17.2.1 COMPANY SNAPSHOT 403
    • 17.2.2 REVENUE ANALYSIS 403
    • 17.2.3 COMPANY SHARE ANALYSIS 404
    • 17.2.4 PRODUCT PORTFOLIO 404
    • 17.2.5 RECENT DEVELOPMENT 404
  • 17.3 HIKMA PHARMACEUTICALS PLC 405
    • 17.3.1 COMPANY SNAPSHOT 405
    • 17.3.2 REVENUE ANALYSIS 405
    • 17.3.3 COMPANY SHARE ANALYSIS 406
    • 17.3.4 PRODUCT PORTFOLIO 406
    • 17.3.5 RECENT DEVELOPMENTS 406
  • 17.4 DR. REDDY'S LABORATORIES LTD 407
    • 17.4.1 COMPANY SNAPSHOT 407
    • 17.4.2 REVENUE ANALYSIS 407
    • 17.4.3 COMPANY SHARE ANALYSIS 408
    • 17.4.4 PRODUCT PORTFOLIO 408
    • 17.4.5 RECENT DEVELOPMENT 409
  • 17.5 BAYER AG 410
    • 17.5.1 COMPANY SNAPSHOT 410
    • 17.5.2 REVENUE ANALYSIS 410
    • 17.5.3 COMPANY SHARE ANALYSIS 411
    • 17.5.4 PRODUCT PORTFOLIO 411
    • 17.5.5 RECENT DEVELOPMENT 411
  • 17.6 AMNEAL PHARMACEUTICAL LLC. 412
    • 17.6.1 COMPANY SNAPSHOT 412
    • 17.6.2 REVENUE ANALYSIS 412
    • 17.6.3 PRODUCT PORTFOLIO 413
    • 17.6.4 RECENT DEVELOPMENTS 413
  • 17.7 APOTEX 414
    • 17.7.1 COMPANY SNAPSHOT 414
    • 17.7.2 PRODUCT PORTFOLIO 414
    • 17.7.3 RECENT DEVELOPMENT 414
  • 17.8 AUROBINDO PHARMA USA 415
    • 17.8.1 COMPANY SNAPSHOT 415
    • 17.8.2 REVENUE ANALYSIS 415
    • 17.8.3 PRODUCT PORTFOLIO 416
    • 17.8.4 RECENT DEVELOPMENT 416
  • 17.9 AVET PHARMACEUTICALS INC. 417
    • 17.9.1 COMPANY SNAPSHOT 417
    • 17.9.2 PRODUCT PORTFOLIO 417
    • 17.9.3 RECENT DEVELOPMENT 417
  • 17.10 ALVOGEN 418
    • 17.10.1 COMPANY SNAPSHOT 418
    • 17.10.2 PRODUCT PORTFOLIO 418
    • 17.10.3 10.3RECENT DEVELOPMENT 418
  • 17.11 ACCORD-UK LTD 419
    • 17.11.1 COMPANY SNAPSHOT 419
    • 17.11.2 PRODUCT PORTFOLIO 419
    • 17.11.3 11.3RECENT DEVELOPMENT 419
  • 17.12 GLAXOSMITHKLINE PLC 420
    • 17.12.1 COMPANY SNAPSHOT 420
    • 17.12.2 REVENUE ANALYSIS 420
    • 17.12.3 PRODUCT PORTFOLIO 421
    • 17.12.4 RECENT DEVELOPMENT 421
  • 17.13 JOHNSON & JOHNSON SERVICES, INC. 422
    • 17.13.1 COMPANY SNAPSHOT 422
    • 17.13.2 REVENUE ANALYSIS 422
    • 17.13.3 PRODUCT PORTFOLIO 423
    • 17.13.4 RECENT DEVELOPMENT 423
  • 17.14 LANNETT 424
    • 17.14.1 COMPANY SNAPSHOT 424
    • 17.14.2 REVENUE ANALYSIS 424
    • 17.14.3 PRODUCT PORTFOLIO 425
    • 17.14.4 RECENT DEVELOPMENT 425
  • 17.15 PRESTIGE CONSUMER HEALTHCARE 426
    • 17.15.1 COMPANY SNAPSHOT 426
    • 17.15.2 REVENUE ANALYSIS 426
    • 17.15.3 PRODUCT PORTFOLIO 427
    • 17.15.4 RECENT DEVELOPMENTS 427
  • 17.16 PFIZER INC. 428
    • 17.16.1 COMPANY SNAPSHOT 428
    • 17.16.2 REVENUE ANALYSIS 428
    • 17.16.3 PRODUCT PORTFOLIO 429
    • 17.16.4 RECENT DEVELOPMENT 429
  • 17.17 RECKITT BENCKISER GROUP PLC. 430
    • 17.17.1 COMPANY SNAPSHOT 430
    • 17.17.2 REVENUE ANALYSIS 430
    • 17.17.3 PRODUCT PORTFOLIO 430
    • 17.17.4 RECENT DEVELOPMENT 431
  • 17.18 SUN PHARMACEUTICAL INDUSTRIES LTD. 432
    • 17.18.1 COMPANY SNAPSHOT 432
    • 17.18.2 REVENUE ANALYSIS 432
    • 17.18.3 PRODUCT PORTFOLIO 433
    • 17.18.4 RECENT DEVELOPMENT 433
  • 17.19 STRIDES PHARMA SCIENCE LIMITED. 434
    • 17.19.1 COMPANY SNAPSHOT 434
    • 17.19.2 REVENUE ANALYSIS 434
    • 17.19.3 PRODUCT PORTFOLIO 435
    • 17.19.4 RECENT DEVELOPMENT 435
  • 17.20 VIATRIS INC. 436
    • 17.20.1 COMPANY SNAPSHOT 436
    • 17.20.2 REVENUE ANALYSIS 436
    • 17.20.3 PRODUCT PORTFOLIO 437
    • 17.20.4 RECENT DEVELOPMENT 437
  • 17.21 VISTA PHARM INC. 438
    • 17.21.1 COMPANY SNAPSHOT 438
    • 17.21.2 PRODUCT PORTFOLIO 438
    • 17.21.3 RECENT DEVELOPMENTS 438
  • 17.22 ZYDUS PHARMACEUTICALS INC., 439
    • 17.22.1 COMPANY SNAPSHOT 439
    • 17.22.2 REVENUE ANALYSIS 439
    • 17.22.3 PRODUCT PORTFOLIO 440
    • 17.22.4 RECENT DEVELOPMENTS 440

18 QUESTIONNAIRE 441

19 RELATED REPORTS 444

LIST OF FIGURES

  • FIGURE 1 GLOBAL INTERSTITIAL CYSTITIS MARKET: SEGMENTATION 61
  • FIGURE 2 GLOBAL INTERSTITIAL CYSTITIS MARKET: DATA TRIANGULATION 64
  • FIGURE 3 GLOBAL BLADDER DISORDERS MARKET: DROC ANALYSIS 65
  • FIGURE 4 GLOBAL INTERSTITIAL CYSTITIS MARKET: GLOBAL VS REGIONAL MARKET ANALYSIS 66
  • FIGURE 5 GLOBAL INTERSTITIAL CYSTITIS MARKET: COMPANY RESEARCH ANALYSIS 66
  • FIGURE 6 GLOBAL INTERSTITIAL CYSTITIS MARKET: INTERVIEW DEMOGRAPHICS 68
  • FIGURE 7 GLOBAL INTERSTITIAL CYSTITIS MARKET: DBMR MARKET POSITION GRID 69
  • FIGURE 8 GLOBAL INTERSTITIAL CYSTITIS MARKET: MARKET APPLICATION COVERAGE GRID 70
  • FIGURE 9 GLOBAL INTERSTITIAL CYSTITIS MARKET: VENDOR SHARE ANALYSIS 71
  • FIGURE 10 GLOBAL INTERSTITIAL CYSTITIS MARKET: SEGMENTATION 74
  • FIGURE 11 RISING EPIDEMIC AND PANDEMIC OUTBREAK AND INCREASING PREVALENCE OF INTERSTITIAL CYSTITIS IS EXPECTED TO DRIVE THE GLOBAL INTERSTITIAL CYSTITIS MARKET IN THE FORECAST PERIOD OF 2022 TO 2029 75
  • FIGURE 12 MILD TO MODERATE SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE GLOBAL INTERSTITIAL CYSTITIS MARKET IN 2022 & 2029 75
  • FIGURE 13 NORTH AMERICA IS EXPECTED TO DOMINATE THE GLOBAL INTERSTITIAL CYSTITIS MARKET AND ASIA-PACIFIC IS EXPECTED TO GROW WITH THE HIGHEST CAGR IN THE FORECAST PERIOD OF 2022 TO 2029 76
  • FIGURE 14 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE GLOBAL INTERSTITIAL CYSTITIS MARKET 85
  • FIGURE 15 GLOBAL INTERSTITIAL CYSTITIS MARKET: BY SEVERITY, 2021 94
  • FIGURE 16 GLOBAL INTERSTITIAL CYSTITIS MARKET: BY SEVERITY, 2022-2029 (USD MILLION) 95
  • FIGURE 17 GLOBAL INTERSTITIAL CYSTITIS MARKET: BY SEVERITY, CAGR (2022-2029) 95
  • FIGURE 18 GLOBAL INTERSTITIAL CYSTITIS MARKET: BY SEVERITY, LIFELINE CURVE 96
  • FIGURE 19 GLOBAL INTERSTITIAL CYSTITIS MARKET: BY TREATMENT TYPE, 2021 99
  • FIGURE 20 GLOBAL INTERSTITIAL CYSTITIS MARKET: BY TREATMENT TYPE, 2022-2029 (USD MILLION) 100
  • FIGURE 21 GLOBAL INTERSTITIAL CYSTITIS MARKET: BY TREATMENT TYPE, CAGR (2022-2029) 100
  • FIGURE 22 GLOBAL INTERSTITIAL CYSTITIS MARKET: BY TREATMENT TYPE, LIFELINE CURVE 101
  • FIGURE 23 GLOBAL INTERSTITIAL CYSTITIS MARKET: BY ROUTE OF ADMINISTRATION, 2021 115
  • FIGURE 24 GLOBAL INTERSTITIAL CYSTITIS MARKET: BY ROUTE OF ADMINISTRATION, 2022-2029 (USD MILLION) 116
  • FIGURE 25 GLOBAL INTERSTITIAL CYSTITIS MARKET: BY ROUTE OF ADMINISTRATION, CAGR (2022-2029) 116
  • FIGURE 26 GLOBAL INTERSTITIAL CYSTITIS MARKET: BY ROUTE OF ADMINISTRATION, LIFELINE CURVE 117
  • FIGURE 27 GLOBAL INTERSTITIAL CYSTITIS MARKET: BY MODE OF PURCHASE, 2021 123
  • FIGURE 28 GLOBAL INTERSTITIAL CYSTITIS MARKET: BY MODE OF PURCHASE, 2022-2029 (USD MILLION) 124
  • FIGURE 29 GLOBAL INTERSTITIAL CYSTITIS MARKET: BY MODE OF PURCHASE, CAGR (2022-2029) 124
  • FIGURE 30 GLOBAL INTERSTITIAL CYSTITIS MARKET: BY MODE OF PURCHASE, LIFELINE CURVE 125
  • FIGURE 31 GLOBAL INTERSTITIAL CYSTITIS MARKET: BY PATIENT TYPE, 2021 128
  • FIGURE 32 GLOBAL INTERSTITIAL CYSTITIS MARKET: BY PATIENT TYPE, 2022-2029 (USD MILLION) 129
  • FIGURE 33 GLOBAL INTERSTITIAL CYSTITIS MARKET: BY PATIENT TYPE, CAGR (2022-2029) 129
  • FIGURE 34 GLOBAL INTERSTITIAL CYSTITIS MARKET: BY PATIENT TYPE, LIFELINE CURVE 130
  • FIGURE 35 GLOBAL INTERSTITIAL CYSTITIS MARKET: BY END USER, 2021 133
  • FIGURE 36 GLOBAL INTERSTITIAL CYSTITIS MARKET: BY END USER, 2022-2029 (USD MILLION) 134
  • FIGURE 37 GLOBAL INTERSTITIAL CYSTITIS MARKET: BY END USER, CAGR (2022-2029) 134
  • FIGURE 38 GLOBAL INTERSTITIAL CYSTITIS MARKET: BY END USER, LIFELINE CURVE 135
  • FIGURE 39 GLOBAL INTERSTITIAL CYSTITIS MARKET: BY DISTRIBUTION CHANNEL, 2021 139
  • FIGURE 40 GLOBAL INTERSTITIAL CYSTITIS MARKET: BY DISTRIBUTION CHANNEL, 2022-2029 (USD MILLION) 140
  • FIGURE 41 GLOBAL INTERSTITIAL CYSTITIS MARKET: BY DISTRIBUTION CHANNEL, CAGR (2022-2029) 140
  • FIGURE 42 GLOBAL INTERSTITIAL CYSTITIS MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE 141
  • FIGURE 43 GLOBAL INTERSTITIAL CYSTITIS MARKET: SNAPSHOT (2021) 146
  • FIGURE 44 GLOBAL INTERSTITIAL CYSTITIS MARKET: BY REGION (2021) 148
  • FIGURE 45 GLOBAL INTERSTITIAL CYSTITIS MARKET: BY REGION (2022 & 2029) 148
  • FIGURE 46 GLOBAL INTERSTITIAL CYSTITIS MARKET: BY REGION (2021 & 2029) 149
  • FIGURE 47 GLOBAL INTERSTITIAL CYSTITIS MARKET: BY SEVERITY (2022-2029) 149
  • FIGURE 48 NORTH AMERICA INTERSTITIAL CYSTITIS MARKET: SNAPSHOT (2021) 152
  • FIGURE 49 NORTH AMERICA INTERSTITIAL CYSTITIS MARKET: BY COUNTRY (2021) 154
  • FIGURE 50 NORTH AMERICA INTERSTITIAL CYSTITIS MARKET: BY COUNTRY (2022 & 2029) 154
  • FIGURE 51 NORTH AMERICA INTERSTITIAL CYSTITIS MARKET: BY COUNTRY (2021 & 2029) 155
  • FIGURE 52 NORTH AMERICA INTERSTITIAL CYSTITIS MARKET: BY SEVERITY (2022-2029) 155
  • FIGURE 53 EUROPE INTERSTITIAL CYSTITIS MARKET: SNAPSHOT (2021) 181
  • FIGURE 54 EUROPE INTERSTITIAL CYSTITIS MARKET: BY COUNTRY (2021) 183
  • FIGURE 55 EUROPE INTERSTITIAL CYSTITIS MARKET: BY COUNTRY (2022 & 2029) 183
  • FIGURE 56 EUROPE INTERSTITIAL CYSTITIS MARKET: BY COUNTRY (2021 & 2029) 184
  • FIGURE 57 EUROPE INTERSTITIAL CYSTITIS MARKET: BY SEVERITY (2022-2029) 184
  • FIGURE 58 ASIA-PACIFIC INTERSTITIAL CYSTITIS MARKET: SNAPSHOT (2021) 253
  • FIGURE 59 ASIA-PACIFIC INTERSTITIAL CYSTITIS MARKET: BY COUNTRY (2021) 255
  • FIGURE 60 ASIA-PACIFIC INTERSTITIAL CYSTITIS MARKET: BY COUNTRY (2022 & 2029) 255
  • FIGURE 61 ASIA-PACIFIC INTERSTITIAL CYSTITIS MARKET: BY COUNTRY (2021 & 2029) 256
  • FIGURE 62 ASIA-PACIFIC INTERSTITIAL CYSTITIS MARKET: BY SEVERITY (2022-2029) 256
  • FIGURE 63 SOUTH AMERICA INTERSTITIAL CYSTITIS MARKET: SNAPSHOT (2021) 331
  • FIGURE 64 SOUTH AMERICA INTERSTITIAL CYSTITIS MARKET: BY COUNTRY (2021) 333
  • FIGURE 65 SOUTH AMERICA INTERSTITIAL CYSTITIS MARKET: BY COUNTRY (2022 & 2029) 333
  • FIGURE 66 SOUTH AMERICA INTERSTITIAL CYSTITIS MARKET: BY COUNTRY (2021 & 2029) 334
  • FIGURE 67 SOUTH AMERICA INTERSTITIAL CYSTITIS MARKET: BY SEVERITY (2022-2029) 334
  • FIGURE 68 MIDDLE EAST AND AFRICA INTERSTITIAL CYSTITIS MARKET: SNAPSHOT (2021) 355
  • FIGURE 69 MIDDLE EAST AND AFRICA INTERSTITIAL CYSTITIS MARKET: BY COUNTRY (2021) 357
  • FIGURE 70 MIDDLE EAST AND AFRICA INTERSTITIAL CYSTITIS MARKET: BY COUNTRY (2022 & 2029) 357
  • FIGURE 71 MIDDLE EAST AND AFRICA INTERSTITIAL CYSTITIS MARKET: BY COUNTRY (2021 & 2029) 358
  • FIGURE 72 MIDDLE EAST AND AFRICA INTERSTITIAL CYSTITIS MARKET: BY SEVERITY (2022-2029) 358
  • FIGURE 73 GLOBAL INTERSTITIAL CYSTITIS MARKET: COMPANY SHARE 2021 (%) 396
  • FIGURE 74 NORTH AMERICA INTERSTITIAL CYSTITIS MARKET: COMPANY SHARE 2021 (%) 397
  • FIGURE 75 EUROPE INTERSTITIAL CYSTITIS MARKET: COMPANY SHARE 2021 (%) 398
  • FIGURE 76 ASIA-PACIFIC INTERSTITIAL CYSTITIS MARKET: COMPANY SHARE 2021 (%) 399